Is Datopotamab the same drug as 8201

Datopotamab (Datopotamab) is not the same as the "8201 drug" that people often call it. The so-called “8201” refers to Trastuzumab Deruxtecan (also known as DS-8201 or T-DXd for short). This drug is a HER2-targeted antibody conjugate drug that has attracted much attention in the field of global cancer treatment in recent years. Although dabrotomabis also derived from Daiichi Sankyo's DXd platform, it has completely different medical positioning in terms of target selection, structural design and indication development direction. The two cannot replace each other, nor can they be regarded as the same type of product.

From a target perspective, there are essential differences between the two. The core of DS-8201 is the trastuzumab antibody, which targets the HER2 protein. HER2 is specifically expressed in breast cancer, gastric cancer, and some lung cancers, so DS-8201 has a clear indication layout in these tumors. Dedabrotuzumab targets the TROP2 protein. This molecule is highly expressed in non-small cell lung cancer, triple-negative breast cancer and other solid tumors. Its biological function is different from HER2, which determines the drug distribution and mode of action of Dedabrotuzumab and DS-8201 No overlap at all. The difference in targets means that the two are not equivalent at the mechanistic level, which also affects their clinical positioning.

In terms of structure, although both belong to the DXd platform ADC (Antibody-Drug Conjugate) developed by Daiichi Sankyo and share the core principle of "cleavable linker + efficient topoisomerase inhibitor payload", they have different antibody parts, different linker optimization strategies, and the drug binding ratio (DAR) has also been adjusted accordingly. These differences at the micro level determine that the two have independent curves in terms of plasma stability, drug release rate after entering tumor cells, tissue selectivity and safety characteristics. In particular, the endocytosis rate of TROP2 is different from that of HER2, so the structural parameters used in dabrotuzumab cannot be simply copied from DS-8201 to ensure that the drug can maintain an ideal concentration and toxicity balance in the target tissue.

In terms of indication expansion, the two development routes are also completely different. DS-8201 has been approved in many countries for use in HER2-positive and even some breast cancers with low HER2 expression, and has gradually been extended to gastric cancer, some lung cancers and other diseases, forming a landmark product for high-HER2 targeted therapy. Dedabrotuzumab is mainly focused on TROP2-high-expressing tumors, including lung cancer and triple-negative breast cancer and other areas with high treatment demand. Overseas research trends also show that dabrotuzumab is more focused on back-line treatment options after standard treatment failure. Its toxicity spectrum, combination therapy potential, and research direction of collaboration with immunotherapy are all on a different clinical path from DS-8201.

In terms of security performance, the two are not interchangeable. DS-8201 focuses more on the risk of interstitial lung disease and certain hematological adverse reactions, while Due to differences in targets and structures, the adverse reactions of dabrotomab focus on different manifestations of skin-related events, mucosal reactions or pulmonary risks, and are often analyzed and dealt with separately in online medical discussions. This shows that although the two share some platform technologies, the biological roots of adverse reactions are completely different, and it also shows that they are not the same drug.

Reference materials:https://dailymed.nlm.nih.gov/